Résumé
Nucleic acid biomarkers are essential for medical diagnosis, particularly in infectious diseases, oncology, and pharmacogenomics. However, current gold standard methods such as polymerase chain reaction (PCR) or next-generation sequencing (NGS) require complex facilities and skilled personnel. This study presents the development of a novel device for a CRISPR-Cas13-based detection of nucleic acid biomarkers at the point-of-care (POC). The studied assay is based on a simplified Specific High Sensitivity Enzymatic Reporter UnLOCKing (SHERLOCK) platform and is implemented in a self-coalescence module (SCM) chip. The development stages focused on optimising the ribonucleoprotein mixture (containing crRNA, Cas13, and reporter) to meet the constraints of the SCM chip, from nanopipetting to reading by epifluorescence microscopy.